APO RESEARCH · REPORT
Parkinson Disease Drug
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Product & engineering
Understand the product.
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Selected research
Market Outlook & Growth Opportunities
Global Parkinson Disease Drug Market Outlook and Growth Opportunities 2026
Market perspective
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
This report provides an overview of the global Parkinson Disease Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Parkinson Disease Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Parkinson Disease Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Parkinson Disease Drug market.
Parkinson Disease Drug Segment by Company
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
Parkinson Disease Drug Segment by Type
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Parkinson Disease Drug Segment by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Parkinson Disease Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Parkinson Disease Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Parkinson Disease Drug key companies, revenue, market share, and recent developments.
3. To split the Parkinson Disease Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Parkinson Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Parkinson Disease Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Parkinson Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parkinson Disease Drug industry.
Chapter 3: Detailed analysis of Parkinson Disease Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Parkinson Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Parkinson Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Parkinson Disease Drug Industry Trends
Table 2. Parkinson Disease Drug Industry Drivers
Table 3. Parkinson Disease Drug Industry Opportunities and Challenges
Table 4. Parkinson Disease Drug Industry Restraints
Table 5. Global Parkinson Disease Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Parkinson Disease Drug Revenue Share by Company (2021-2026)
Table 7. Global Parkinson Disease Drug Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Parkinson Disease Drug Key Company Manufacturing Base & Headquarters
Table 9. Global Parkinson Disease Drug Company, Product Type & Application
Table 10. Global Parkinson Disease Drug Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Parkinson Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Sinemet-CR
Table 15. Significant Companies of Trastal
Table 16. Significant Companies of Madopar
Table 17. Significant Companies of COMT Inhibitor
Table 18. Significant Companies of Other
Table 19. Global Parkinson Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 20. Global Parkinson Disease Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 21. Global Parkinson Disease Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 22. Global Parkinson Disease Drug Sales Value Share by Type (2021-2026)
Table 23. Global Parkinson Disease Drug Sales Value Share by Type (2027-2032)
Table 24. Significant Companies of Under 40 Years Old
Table 25. Significant Companies of 40-65 Years Old
Table 26. Significant Companies of Above 65 Years Old
Table 27. Global Parkinson Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 28. Global Parkinson Disease Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 29. Global Parkinson Disease Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 30. Global Parkinson Disease Drug Sales Value Share by Application (2021-2026)
Table 31. Global Parkinson Disease Drug Sales Value Share by Application (2027-2032)
Table 32. Global Parkinson Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 33. Global Parkinson Disease Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 34. Global Parkinson Disease Drug Sales Value Share by Region (2021-2026)
Table 35. Global Parkinson Disease Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 36. Global Parkinson Disease Drug Sales Value Share by Region (2027-2032)
Table 37. Global Parkinson Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Parkinson Disease Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 39. Global Parkinson Disease Drug Sales Value Market Share by Country (2021-2026)
Table 40. Global Parkinson Disease Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 41. Global Parkinson Disease Drug Sales Value Market Share by Country (2027-2032)
Table 42. Merck Company Information
Table 43. Merck Business Overview
Table 44. Merck Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 45. Merck Parkinson Disease Drug Product Portfolio
Table 46. Merck Recent Development
Table 47. Akorn Company Information
Table 48. Akorn Business Overview
Table 49. Akorn Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. Akorn Parkinson Disease Drug Product Portfolio
Table 51. Akorn Recent Development
Table 52. GSK Company Information
Table 53. GSK Business Overview
Table 54. GSK Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 55. GSK Parkinson Disease Drug Product Portfolio
Table 56. GSK Recent Development
Table 57. Novartis Company Information
Table 58. Novartis Business Overview
Table 59. Novartis Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 60. Novartis Parkinson Disease Drug Product Portfolio
Table 61. Novartis Recent Development
Table 62. Boehringer Ingelheim Company Information
Table 63. Boehringer Ingelheim Business Overview
Table 64. Boehringer Ingelheim Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
Table 66. Boehringer Ingelheim Recent Development
Table 67. Teva Pharmaceutical Company Information
Table 68. Teva Pharmaceutical Business Overview
Table 69. Teva Pharmaceutical Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 70. Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
Table 71. Teva Pharmaceutical Recent Development
Table 72. Abbvie Company Information
Table 73. Abbvie Business Overview
Table 74. Abbvie Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 75. Abbvie Parkinson Disease Drug Product Portfolio
Table 76. Abbvie Recent Development
Table 77. Kyowa Hakko Kirin Pharma Company Information
Table 78. Kyowa Hakko Kirin Pharma Business Overview
Table 79. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
Table 81. Kyowa Hakko Kirin Pharma Recent Development
Table 82. Astellas Pharma Company Information
Table 83. Astellas Pharma Business Overview
Table 84. Astellas Pharma Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 85. Astellas Pharma Parkinson Disease Drug Product Portfolio
Table 86. Astellas Pharma Recent Development
Table 87. Desitin Arzneimittel Company Information
Table 88. Desitin Arzneimittel Business Overview
Table 89. Desitin Arzneimittel Parkinson Disease Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 90. Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
Table 91. Desitin Arzneimittel Recent Development
Table 92. Endo Pharmaceuticals Company Information
Table 93. Endo Pharmaceuticals Business Overview
Table 94. Endo Pharmaceuticals Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 95. Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
Table 96. Endo Pharmaceuticals Recent Development
Table 97. F.Hoffmann-La Roche Company Information
Table 98. F.Hoffmann-La Roche Business Overview
Table 99. F.Hoffmann-La Roche Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 100. F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
Table 101. F.Hoffmann-La Roche Recent Development
Table 102. H.Lundbeck Company Information
Table 103. H.Lundbeck Business Overview
Table 104. H.Lundbeck Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 105. H.Lundbeck Parkinson Disease Drug Product Portfolio
Table 106. H.Lundbeck Recent Development
Table 107. Valeant Company Information
Table 108. Valeant Business Overview
Table 109. Valeant Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 110. Valeant Parkinson Disease Drug Product Portfolio
Table 111. Valeant Recent Development
Table 112. Apokyn Company Information
Table 113. Apokyn Business Overview
Table 114. Apokyn Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 115. Apokyn Parkinson Disease Drug Product Portfolio
Table 116. Apokyn Recent Development
Table 117. Orion Company Information
Table 118. Orion Business Overview
Table 119. Orion Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 120. Orion Parkinson Disease Drug Product Portfolio
Table 121. Orion Recent Development
Table 122. Stada Arzneimittel Company Information
Table 123. Stada Arzneimittel Business Overview
Table 124. Stada Arzneimittel Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 125. Stada Arzneimittel Parkinson Disease Drug Product Portfolio
Table 126. Stada Arzneimittel Recent Development
Table 127. US WorldMeds Company Information
Table 128. US WorldMeds Business Overview
Table 129. US WorldMeds Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 130. US WorldMeds Parkinson Disease Drug Product Portfolio
Table 131. US WorldMeds Recent Development
Table 132. Bausch Health Company Information
Table 133. Bausch Health Business Overview
Table 134. Bausch Health Parkinson Disease Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 135. Bausch Health Parkinson Disease Drug Product Portfolio
Table 136. Bausch Health Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Authors List of This Report
Table 139. Secondary Sources
Table 140. Primary Sources
List of Figures
Figure 1. Parkinson Disease Drug Product Image
Figure 2. Global Parkinson Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Parkinson Disease Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Parkinson Disease Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Sinemet-CR Image
Figure 8. Trastal Image
Figure 9. Madopar Image
Figure 10. COMT Inhibitor Image
Figure 11. Other Image
Figure 12. Global Parkinson Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 13. Global Parkinson Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 14. Global Parkinson Disease Drug Sales Value Share by Type (2021-2032)
Figure 15. Under 40 Years Old Image
Figure 16. 40-65 Years Old Image
Figure 17. Above 65 Years Old Image
Figure 18. Global Parkinson Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Parkinson Disease Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Parkinson Disease Drug Sales Value Share by Application (2021-2032)
Figure 21. Global Parkinson Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 22. Global Parkinson Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 23. North America Parkinson Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 24. North America Parkinson Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Europe Parkinson Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 26. Europe Parkinson Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Asia-Pacific Parkinson Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 28. Asia-Pacific Parkinson Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 29. South America Parkinson Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 30. South America Parkinson Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Middle East & Africa Parkinson Disease Drug Sales Value (2021-2032) & (US$ Million)
Figure 32. Middle East & Africa Parkinson Disease Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 33. USA Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. USA Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. USA Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Canada Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Canada Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Canada Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Mexico Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Mexico Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Mexico Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Germany Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Germany Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Germany Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. France Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. France Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. France Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. U.K. Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. U.K. Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. U.K. Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Italy Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Italy Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Italy Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Spain Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Spain Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Spain Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Russia Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Russia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Russia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Netherlands Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Netherlands Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Netherlands Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Nordic Countries Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Nordic Countries Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. China Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. China Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. China Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. Japan Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. Japan Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. Japan Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. South Korea Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. South Korea Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. South Korea Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. India Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. India Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. India Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Australia Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Australia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Australia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Southeast Asia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Southeast Asia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Brazil Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Brazil Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Brazil Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Argentina Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Argentina Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Argentina Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Chile Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Chile Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Chile Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Colombia Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Colombia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Colombia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Peru Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Peru Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Peru Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Saudi Arabia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Saudi Arabia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Israel Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Israel Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Israel Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. UAE Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. UAE Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. UAE Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Turkey Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Turkey Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Turkey Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Iran Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Iran Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Iran Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Egypt Parkinson Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Egypt Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Egypt Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Years Considered
Figure 118. Research Process
Figure 119. Key Executives Interviewed
Scope & coverage.
Types
- Sinemet-CR
- Trastal
- Madopar
- COMT Inhibitor
- Other
Applications
- Under 40 Years Old
- 40-65 Years Old
- Above 65 Years Old
Companies covered
- Merck
- Akorn
- GSK
- Novartis
- Boehringer Ingelheim
- Teva Pharmaceutical
- Abbvie
- Kyowa Hakko Kirin Pharma
- Astellas Pharma
- Desitin Arzneimittel
- Endo Pharmaceuticals
- F.Hoffmann-La Roche
- H.Lundbeck
- Valeant
- Apokyn
- Orion
- Stada Arzneimittel
- US WorldMeds
- Bausch Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Parkinson Disease Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Parkinson Disease Drug Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Parkinson Disease Drug Market Dynamics
- 2.1 Parkinson Disease Drug Industry Trends
- 2.2 Parkinson Disease Drug Industry Drivers
- 2.3 Parkinson Disease Drug Industry Opportunities and Challenges
- 2.4 Parkinson Disease Drug Industry Restraints
3 Parkinson Disease Drug Market by Company
- 3.1 Global Parkinson Disease Drug Company Revenue Ranking in 2025
- 3.2 Global Parkinson Disease Drug Revenue by Company (2021-2026)
- 3.3 Global Parkinson Disease Drug Company Ranking (2024-2026)
- 3.4 Global Parkinson Disease Drug Company Manufacturing Base and Headquarters
- 3.5 Global Parkinson Disease Drug Company Product Type and Application
- 3.6 Global Parkinson Disease Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Parkinson Disease Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Parkinson Disease Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Parkinson Disease Drug Market by Type
- 4.1 Parkinson Disease Drug Type Introduction
- 4.1.1 Sinemet-CR
- 4.1.2 Trastal
- 4.1.3 Madopar
- 4.1.4 COMT Inhibitor
- 4.1.5 Other
- 4.2 Global Parkinson Disease Drug Sales Value by Type
- 4.2.1 Global Parkinson Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Parkinson Disease Drug Sales Value by Type (2021-2032)
- 4.2.3 Global Parkinson Disease Drug Sales Value Share by Type (2021-2032)
5 Parkinson Disease Drug Market by Application
- 5.1 Parkinson Disease Drug Application Introduction
- 5.1.1 Under 40 Years Old
- 5.1.2 40-65 Years Old
- 5.1.3 Above 65 Years Old
- 5.2 Global Parkinson Disease Drug Sales Value by Application
- 5.2.1 Global Parkinson Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Parkinson Disease Drug Sales Value by Application (2021-2032)
- 5.2.3 Global Parkinson Disease Drug Sales Value Share by Application (2021-2032)
6 Parkinson Disease Drug Regional Value Analysis
- 6.1 Global Parkinson Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Parkinson Disease Drug Sales Value by Region (2021-2032)
- 6.2.1 Global Parkinson Disease Drug Sales Value by Region: 2021-2026
- 6.2.2 Global Parkinson Disease Drug Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Parkinson Disease Drug Sales Value (2021-2032)
- 6.3.2 North America Parkinson Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Parkinson Disease Drug Sales Value (2021-2032)
- 6.4.2 Europe Parkinson Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Parkinson Disease Drug Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Parkinson Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Parkinson Disease Drug Sales Value (2021-2032)
- 6.6.2 South America Parkinson Disease Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Parkinson Disease Drug Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Parkinson Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Parkinson Disease Drug Country-level Value Analysis
- 7.1 Global Parkinson Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Parkinson Disease Drug Sales Value by Country (2021-2032)
- 7.2.1 Global Parkinson Disease Drug Sales Value by Country (2021-2026)
- 7.2.2 Global Parkinson Disease Drug Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.7.2 France Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 China Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 India Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Parkinson Disease Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Parkinson Disease Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Parkinson Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Merck
- 8.1.1 Merck Company Information
- 8.1.2 Merck Business Overview
- 8.1.3 Merck Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.1.4 Merck Parkinson Disease Drug Product Portfolio
- 8.1.5 Merck Recent Developments
- 8.2 Akorn
- 8.2.1 Akorn Company Information
- 8.2.2 Akorn Business Overview
- 8.2.3 Akorn Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.2.4 Akorn Parkinson Disease Drug Product Portfolio
- 8.2.5 Akorn Recent Developments
- 8.3 GSK
- 8.3.1 GSK Company Information
- 8.3.2 GSK Business Overview
- 8.3.3 GSK Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.3.4 GSK Parkinson Disease Drug Product Portfolio
- 8.3.5 GSK Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Parkinson Disease Drug Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Boehringer Ingelheim
- 8.5.1 Boehringer Ingelheim Company Information
- 8.5.2 Boehringer Ingelheim Business Overview
- 8.5.3 Boehringer Ingelheim Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
- 8.5.5 Boehringer Ingelheim Recent Developments
- 8.6 Teva Pharmaceutical
- 8.6.1 Teva Pharmaceutical Company Information
- 8.6.2 Teva Pharmaceutical Business Overview
- 8.6.3 Teva Pharmaceutical Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
- 8.6.5 Teva Pharmaceutical Recent Developments
- 8.7 Abbvie
- 8.7.1 Abbvie Company Information
- 8.7.2 Abbvie Business Overview
- 8.7.3 Abbvie Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.7.4 Abbvie Parkinson Disease Drug Product Portfolio
- 8.7.5 Abbvie Recent Developments
- 8.8 Kyowa Hakko Kirin Pharma
- 8.8.1 Kyowa Hakko Kirin Pharma Company Information
- 8.8.2 Kyowa Hakko Kirin Pharma Business Overview
- 8.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
- 8.8.5 Kyowa Hakko Kirin Pharma Recent Developments
- 8.9 Astellas Pharma
- 8.9.1 Astellas Pharma Company Information
- 8.9.2 Astellas Pharma Business Overview
- 8.9.3 Astellas Pharma Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
- 8.9.5 Astellas Pharma Recent Developments
- 8.10 Desitin Arzneimittel
- 8.10.1 Desitin Arzneimittel Company Information
- 8.10.2 Desitin Arzneimittel Business Overview
- 8.10.3 Desitin Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
- 8.10.5 Desitin Arzneimittel Recent Developments
- 8.11 Endo Pharmaceuticals
- 8.11.1 Endo Pharmaceuticals Company Information
- 8.11.2 Endo Pharmaceuticals Business Overview
- 8.11.3 Endo Pharmaceuticals Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
- 8.11.5 Endo Pharmaceuticals Recent Developments
- 8.12 F.Hoffmann-La Roche
- 8.12.1 F.Hoffmann-La Roche Company Information
- 8.12.2 F.Hoffmann-La Roche Business Overview
- 8.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
- 8.12.5 F.Hoffmann-La Roche Recent Developments
- 8.13 H.Lundbeck
- 8.13.1 H.Lundbeck Company Information
- 8.13.2 H.Lundbeck Business Overview
- 8.13.3 H.Lundbeck Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
- 8.13.5 H.Lundbeck Recent Developments
- 8.14 Valeant
- 8.14.1 Valeant Company Information
- 8.14.2 Valeant Business Overview
- 8.14.3 Valeant Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.14.4 Valeant Parkinson Disease Drug Product Portfolio
- 8.14.5 Valeant Recent Developments
- 8.15 Apokyn
- 8.15.1 Apokyn Company Information
- 8.15.2 Apokyn Business Overview
- 8.15.3 Apokyn Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.15.4 Apokyn Parkinson Disease Drug Product Portfolio
- 8.15.5 Apokyn Recent Developments
- 8.16 Orion
- 8.16.1 Orion Company Information
- 8.16.2 Orion Business Overview
- 8.16.3 Orion Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.16.4 Orion Parkinson Disease Drug Product Portfolio
- 8.16.5 Orion Recent Developments
- 8.17 Stada Arzneimittel
- 8.17.1 Stada Arzneimittel Company Information
- 8.17.2 Stada Arzneimittel Business Overview
- 8.17.3 Stada Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
- 8.17.5 Stada Arzneimittel Recent Developments
- 8.18 US WorldMeds
- 8.18.1 US WorldMeds Company Information
- 8.18.2 US WorldMeds Business Overview
- 8.18.3 US WorldMeds Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
- 8.18.5 US WorldMeds Recent Developments
- 8.19 Bausch Health
- 8.19.1 Bausch Health Company Information
- 8.19.2 Bausch Health Business Overview
- 8.19.3 Bausch Health Parkinson Disease Drug Revenue and Gross Margin (2021-2026)
- 8.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
- 8.19.5 Bausch Health Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst